Dr. Roger J. Pomerantz

Chairman

Dr. Roger J. Pomerantz has a biomedical career that spans key senior leadership positions in academic medicine, small and large biopharmaceutical organizations, global therapeutic franchises, and business development, licensing, and acquisitions at world-wide pharmaceutical companies. He has led the development of 14 large and small molecule therapies for HIV, HCV, MDR-TB, CMV, and C Diff, which have been approved and launched globally.

He was the President, CEO and Chairman of Seres Therapeutics, the first publicly traded microbiome therapeutics company. Pomerantz held senior roles at multiple pharmaceutical companies, including as the Global Head of Infectious Disease at Johnson & Johnson and Head of Licensing and Acquisitions at Merck. He was a Venture Partner at Flagship Pioneering.

Pomerantz currently serves on Boards of Directors for multiple life sciences companies, including Enlivex Therapeutics, Indaptus Therapeutics, !E Therapeutics and CollPlant. He has published over 300 articles in scientific literature and presented over 300 invited lectures, nationally and internationally.

Pomerantz received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at The Johns Hopkins School of Medicine. He completed his Internal Medicine internship and residency training, and his subspecialty clinical and research training in Infectious Diseases and Virology at the Massachusetts General Hospital (M.G.H.) of the Harvard Medical School, and was selected and served as the Chief Medical Resident at Massachusetts General Hospital. His post-doctoral research training in Molecular Retrovirology was obtained at both the Harvard Medical School and the Whitehead Institute of the Massachusetts Institute of Technology (M.I.T.). Pomerantz is Board Certified in both Internal Medicine and Infectious Diseases.